The following are short summaries of recent CBP NY rulings issued by the agency's National Commodity Specialist Division in New York:
The following are short summaries of recent CBP NY rulings issued by the agency's National Commodity Specialist Division in New York:
The Customs Rulings Online Search System (CROSS) was updated March 28 with the following headquarters rulings (ruling revocations and modifications will be detailed elsewhere in a separate article as they are announced in the Customs Bulletin):
The following are short summaries of recent CBP NY rulings issued by the agency's National Commodity Specialist Division in New York:
The Customs Rulings Online Search System (CROSS) was updated March 25 with the following headquarters rulings (ruling revocations and modifications will be detailed elsewhere in a separate article as they are announced in the Customs Bulletin):
The Customs Rulings Online Search System (CROSS) was updated March 19 with the following headquarters rulings (ruling revocations and modifications will be detailed elsewhere in a separate article as they are announced in the Customs Bulletin):
The Customs Rulings Online Search System (CROSS) was updated March 15-18 with the following headquarters rulings (ruling revocations and modifications will be detailed elsewhere in a separate article as they are announced in the Customs Bulletin):
The Customs Rulings Online Search System (CROSS) was updated March 15 with the following headquarters rulings (ruling revocations and modifications will be detailed elsewhere in a separate article as they are announced in the Customs Bulletin):
Certain types of circular welded non-alloy steel pipe exported from the U.S. to Mexico for reprocessing and subsequent re-importation are not covered by the antidumping duty order on Mexican standard pipe, the Commerce Department said in a March 13 scope ruling. The products’ country of origin is the U.S., not Mexico, the department said.
CBP ruled that the fallback method was appropriate for appraising several pharmaceutical products being imported for use in clinical trials. The ruling, dated Feb. 28, looked at three different valuation scenarios, each for pharmaceutical products that were provided to the importer conducting the clinical trial by related companies but were not actually sold.